CHITOGENX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.045 CAD | 0.00% |
|
+12.50% | -30.77% |
| Feb. 28 | Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors | CI |
| Feb. 28 | Chitogenx Inc. Announces CEO Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 13.27M 18.14M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -5.47M | Net income 2023 | -6M -8.2M | EV / Sales 2022 | - |
| Net Debt 2022 | 5.4M 7.38M | Net Debt 2023 | 6.21M 8.49M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.45
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.75% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +12.50% | ||
| Current month | +12.50% | ||
| 1 month | +12.50% | ||
| 3 months | -47.06% | ||
| 6 months | -50.00% | ||
| Current year | -30.77% |
1 week
0.05
0.05
1 month
0.040.07
Current year
0.030.10
1 year
0.030.17
3 years
0.030.60
5 years
0.030.99
10 years
0.031.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Laurin
CEO | Chief Executive Officer | 63 | 19-06-18 |
Luc Mainville
DFI | Director of Finance/CFO | 60 | 18-09-17 |
Mukesh Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pierre Laurin
CEO | Chief Executive Officer | 63 | 19-06-18 |
Steven Saviuk
BRD | Director/Board Member | 65 | 15-02-04 |
| Director/Board Member | 62 | 21-06-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.045 | +12.50% | 48,800 |
Delayed Quote Canadian Securities Exchange, May 03, 2024 at 10:12 am EDT
More quotes
ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Companyâs proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.
Calendar
2024-05-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -30.77% | 2.73M | |
| +22.81% | 47.9B | |
| +46.56% | 41.42B | |
| -1.88% | 40.7B | |
| -6.20% | 28.92B | |
| +11.33% | 25.55B | |
| -21.00% | 19.27B | |
| -1.43% | 12.15B | |
| +30.73% | 12.14B | |
| -0.48% | 11.99B |
- Stock Market
- Equities
- CHGX Stock